Retatrutide Trial in Obesity and CVD Concludes After 113 Weeks | Retatrutide News

A study on retatrutide's efficacy and safety in obesity and cardiovascular disease has concluded. The trial, lasting 113 weeks, is part of Eli Lilly's m...
Clinical Trials · October 28, 2026